Biocompatible orthodontic cement with antibacterial capabili
White spot lesions (WSLs) often occur in orthodontic treatments. A newer cement reduces the occurrence of these spots, finds a study.

The objectives of this study were to develop a novel orthodontic cement using particles of nanosilver (NAg), N-acetylcysteine (NAC), and 2-methacryloyloxyethyl phosphorylcholine (MPC), and to investigate the effects on bonding strength, biofilms, and biocompatibility.

A commercial resin-modified glass ionomer cement (RMGIC) was modified by adding NAg, NAC, and MPC. The unmodified RMGIC served as the control. Enamel bond strength and cytotoxicity of the cements were investigated. The protein repellent behavior of cements was also evaluated. The metabolic assay, lactic acid production assay, and colony-forming unit assay of biofilms were used to determine the antibacterial capability of cements.

- The new bioactive cement with NAg, NAC, and MPC had clinically acceptable bond strength and biocompatibility.

- Compared to commercial control, the new cement suppressed metabolic activity and lactic acid production of biofilms by 59.03% and 70.02% respectively, reduced biofilm CFU by 2 logs, and reduced protein adsorption by 76.87%.

Conclusively, the new cement with NAg, NAC, and MPC had strong antibacterial capability, protein-repellent ability, and acceptable biocompatibility. The new cement is promising to protect the enamel from demineralization during orthodontic treatments.

BMC Oral Health